Tag
Michael Polansky’s Outer Bio launched with $23M and an unusual pitch: not a drug company, but an AI platform screening compounds on living human skin.
Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.
The all-stock reverse merger, paired with a $278 million private placement, creates a Nasdaq-listed company built around CLD-423 for inflammatory bowel disease.
Shares jumped 56% on debut as the biotech advances oxnimbi, a once-nightly pill targeting an underlying cause of obstructive sleep apnea, toward a 2027 FDA decision.
The cardiac-myosin inhibitor developer priced one of the year’s larger biotech IPOs to fund BHB-1893, a would-be rival to Bristol Myers’ Camzyos for a serious heart-muscle disease.
The company’s long-acting retina treatment failed to prove non-inferiority to standard therapy across the full trial, wiping out nearly $1 billion in market value.
The world’s largest biosimilar maker will commercialize up to 10 Henlius-developed copies of blockbuster biologics globally, positioning for one of the industry’s biggest-ever patent cliffs.
The all-stock merger of equals unites Supernus’s brain-disorder portfolio with Indivior’s addiction treatments, forming a company with 11 marketed drugs.
Prediction-market firm Kalshi has opened contracts on whether drugs will hit their endpoints or win FDA approval, raising fresh insider-trading and ethics concerns.
The drugmaker added $1 billion to its savings target and raised its 2026 revenue outlook, even as COVID sales collapse and several cancer drugs slip.
The AI-first primary-care startup adds Summer Health’s text-based pediatric service and a 100,000-message dataset to cover care ‘from birth through adulthood.’
The digital musculoskeletal-care company is expanding into gut health — a huge, underserved market — with plans for one combined app in 2027.